Sagimet Biosciences Inc. Series A (SGMT)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 31/100 (MEDIUM), 79.1 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: ?% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Sagimet Biosciences Highlights 52-Week Acne Data, Sets U.S. Phase III Trial Launch
- Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
- Sagimet Biosciences Shares Rise 12% After Denifanstat Phase 3 Acne Trial Data
- Sagimet Raises $115M At Premium To Fund Phase 3 Acne Drug Trial – SGMT Stock Surges Pre-Market
- Sagimet Prices $115 Million Offering of Series A Shares, Warrants; Shares Rise Pre-Bell
- Sagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
- Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026
- Sagimet Biosciences to Host Virtual KOL Event, “Denifanstat Update: 52-Week Data from Phase 3 Open-Label Extension in China and Planned AURORA Phase 3 Clinical Trial in US” on September 30, 2026
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors? — Neuro Oncol 2024 Oct 3 PMID 38912846
- Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma. — Clin Cancer Res 2024 May 15 PMID 38446982
- Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference. — Lancet Oncol 2023 Apr PMID 36990614
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Sagimet Biosciences Inc. Series A.
Full SGMT Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.